Rezolute (NASDAQ:RZLT) Now Covered by Analysts at Lake Street Capital

Equities researchers at Lake Street Capital assumed coverage on shares of Rezolute (NASDAQ:RZLT) in a report issued on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $9.00 price target on the stock. Lake Street Capital’s price objective would suggest a potential upside of 120.05% from the company’s previous close.

Other research analysts have also issued research reports about the company. Craig Hallum raised Rezolute from a “hold” rating to a “buy” rating and raised their price objective for the company from $4.00 to $7.00 in a research report on Tuesday. Citizens Jmp raised Rezolute from a “market perform” rating to an “outperform” rating and set a $11.00 target price on the stock in a research note on Wednesday, June 3rd. Zacks Research raised Rezolute from a “strong sell” rating to a “hold” rating in a research report on Friday, August 14th. Wedbush upped their price target on shares of Rezolute from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 3rd. Finally, HC Wainwright raised their price objective on shares of Rezolute from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, September 25th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.44.

Rezolute Price Performance

NASDAQ:RZLT opened at $4.09 on Wednesday. The firm has a market capitalization of $395.59 million, a P/E ratio of -5.38 and a beta of 0.60. Rezolute has a one year low of $1.07 and a one year high of $11.46. The company’s 50-day simple moving average is $4.55 and its 200 day simple moving average is $4.04.

Rezolute (NASDAQ:RZLT) last announced its earnings results on Thursday, September 24th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). On average, equities research analysts expect that Rezolute will post -0.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Rezolute

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jennison Associates LLC purchased a new position in Rezolute during the first quarter valued at $10,489,000. Siren L.L.C. bought a new position in shares of Rezolute in the first quarter worth about $10,151,000. Dimensional Fund Advisors LP grew its stake in shares of Rezolute by 273.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 530,229 shares of the company’s stock valued at $1,617,000 after acquiring an additional 388,346 shares during the period. Bank of New York Mellon Corp purchased a new stake in Rezolute in the 2nd quarter worth approximately $1,104,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Rezolute during the 4th quarter worth approximately $494,000. Hedge funds and other institutional investors own 82.97% of the company’s stock.

More Rezolute News

Here are the key news stories impacting Rezolute this week:

• Positive Sentiment: Craig-Hallum upgraded Rezolute from “Hold” to “Buy” and raised its price target to $7 from $4, signaling increased confidence in the company’s outlook. Craig-Hallum upgrades Rezolute to Buy from Hold
• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $10 price target while projecting a significant improvement in profitability over the long term. Its estimates rise to $1.42 in EPS for fiscal 2030 and $2.94 for fiscal 2031, compared with continued losses in the nearer-term years. Rezolute Stock Earnings Estimates Decreased by HC Wainwright
• Neutral Sentiment: The unchanged $10 HC Wainwright target provides a more optimistic valuation framework than the current share price, but the estimates depend on Rezolute reaching profitability later in the decade. The company remains unprofitable, with analysts expecting a loss for the current fiscal year.
• Negative Sentiment: HC Wainwright reduced several near- and medium-term EPS forecasts: fiscal 2027 EPS was lowered to $(0.57) from $(0.45), Q1 2027 to $(0.16) from $(0.12), Q2 2027 to $(0.14) from $(0.10), and Q4 2027 to $(0.13) from $(0.09). Fiscal 2028 was also trimmed slightly to $(0.34) from $(0.33), suggesting higher anticipated losses before a projected turnaround.

Rezolute Company Profile

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare and metabolic diseases. The company’s research is centered on therapies that address abnormal insulin activity and other conditions involving disrupted glucose regulation.

Rezolute’s leading product candidate is RZ358, an investigational monoclonal antibody designed to reduce the effects of excessive insulin. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas produces too much insulin and causes potentially severe, recurrent hypoglycemia.